Analyzing Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP)

NLS Pharmaceutics (NASDAQ:NLSP) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Risk & Volatility

NLS Pharmaceutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Institutional and Insider Ownership

12.7% of Atossa Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 7.6% of Atossa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NLS Pharmaceutics and Atossa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Atossa Therapeutics	N/A	-35.74%	-33.51%

Analyst Ratings

This is a summary of current ratings and recommmendations for NLS Pharmaceutics and Atossa Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	0	0	0	0	0.00
Atossa Therapeutics	0	0	3	0	3.00

Atossa Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 635.53%. Given Atossa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Atossa Therapeutics is more favorable than NLS Pharmaceutics.

Earnings and Valuation

This table compares NLS Pharmaceutics and Atossa Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$12.17 million	N/A	N/A
Atossa Therapeutics	N/A	N/A	-$30.09 million	($0.22)	-4.33

Summary

Atossa Therapeutics beats NLS Pharmaceutics on 5 of the 9 factors compared between the two stocks.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

About Atossa Therapeutics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.